HumanX Announces Preliminary Agenda
|
Main Logo
Alex Zhavoronkov
Alex Zhavoronkov
CEO
Insilico Medicine

Alex is the founder and CEO of Insilico Medicine, a clinical-stage biotech company developing next-generation generative AI and robotics platforms for drug discovery. Since 2021, the company nominated 18 preclinical candidates, started 6 human clinical trials, and entered Phase II with an AI-discovered novel target and AI-designed novel molecule. By 2023, 11 out of the top 20 pharmaceutical companies used a part of the Pharma.AI software suite, and the IND-stage cancer program was sold in a deal with $80 million upfront as a testament to the quality and novelty of the AI-generated molecule.